ACN vs STX

Accenture (ACN) exhibits mixed fundamental health, with a Piotroski F-Score of 4/9 indicating a borderline stable financial position, and no Altman Z-Score available to assess distress risk. The stock trades at a premium to its Graham Number ($116.86) and intrinsic value estimate ($84.7), suggesting valuation is driven by growth expectations rather than conservative safety. Despite strong profitability metrics—ROE of 25.02% and gross margin of 31.97%—earnings growth has turned negative (-1.60% YoY), and recent price performance reflects significant underperformance over 1Y (-39.2%) and 5Y (-20.8%). Analysts remain optimistic with a buy recommendation and a target price of $268.51, but insider activity is neutral, and technical trends are bearish.

STX exhibits a stable Piotroski F-Score of 6/9, but the financial profile is characterized by extreme leverage and a significant valuation disconnect. While earnings and revenue growth are explosive (Earnings +67.7% YoY), the current price of $547.75 trades at a massive premium to its Intrinsic Value ($261.66) and Graham Number ($20.49). The stock has experienced a parabolic 1-year gain of 632%, leaving it trading above the average analyst target price of $508.47. High debt-to-equity and bearish insider activity suggest the current rally may be overextended.